ADD/ADHD News

Newly licensed adolescents with attention-deficit/hyperactivity disorder are 1.36 times more likely to experience a vehicular crash than teenagers without the condition, according to a study published in JAMA Pediatrics.

ADHD medication use was associated with better performance on higher education entrance tests among individuals with ADHD, according to recent findings.

Recent findings indicated associations between hyperactive amygdala responses and regions responsible for emotional processing with high levels of psychosocial stress in adolescents with greater conduct and hyperactivity/inattention problems.

The FDA recently approved Mydayis, a once-daily mixed salts of a single-entity amphetamine product from Shire, for treatment of ADHD in individuals aged 13 years and older.

Autism was associated with an increased risk for violent crime; however, the association was significantly attenuated by comorbid ADHD or conduct disorder, according to recent findings.

Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged 6 to 17 years.

Prenatal antidepressant use and risk for ADHD may be partially due to confounding by indication of antidepressants, according to recent findings.

Black and Hispanic children enrolled in Medicaid are significantly more likely to discontinue pharmacological treatment for attention-deficit/hyperactivity disorder when compared with Medicaid-enrolled white children, according to study results.

SAN DIEGO — Data presented at the American Psychiatric Association Annual Meeting indicated efficacy and safety of HLD200, a delayed-release and extended-release formulation of methylphenidate from Ironshore Pharmaceuticals, for morning and evening functioning in pediatric ADHD.

SAN DIEGO — In this video, Frances Levin, MD, of Columbia University and NewYork-Presbyterian Hospital, reviews current research on treatment approaches for concurrent cannabis use disorder and ADHD.